Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: A critical appraisal from a systematic review of the literature

Haematologica

Volumn 93, Issue 1, 2008, Pages 98-103

  Ruggeri, Marco ^a   Fortuna, Stefania ^a   Rodeghiero, Francesco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Diagnosis; Idiopathic thrombocytopenic purpura; ITP; Systematic review; Terminology; Therapy

Indexed keywords

ARTICLE; BLEEDING TENDENCY; CLINICAL EVALUATION; CLINICAL STUDY; DATA EXTRACTION; DIAGNOSTIC PROCEDURE; DISEASE DURATION; DISEASE SEVERITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LITERATURE; MEDICAL RESEARCH; NOMENCLATURE; REFRACTORY THROMBOCYTOPENIA; SPLENECTOMY; STANDARDIZATION; THROMBOCYTE COUNT; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; BLOOD PLATELETS; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; HEMATOLOGY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; PLATELET COUNT; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RISK; SPLENECTOMY; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 38549107956     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11582     Document Type: Article

References (84)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995-1008.
2. McMillan R. The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura. Semin Hematol 2000;37:5-9.
3. Werlhof PG Opera Omnia. Hannover Helwing 748. In: Classic Descriptions of Disease. 3rd ed., edited by RH Major. Thomas CC, Springfield; IL, USA. 1965.
4. Cooper N, Bussel JBJ. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006;133:364-74.
5. Provan D, Newlan A, Norfolk D, Bolton-Maggs B, Lilleyman J, Greer I, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura (ITP) in adults, children and in pregnancy. Br J Haematol 2003;120:574-96.
6. George JN, Woolf SH, Raskob GE, Wasser JS, Alendort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods of American Society of Hematology. Blood 1996;88:3-40.
7. Cines DB, Bussel JB. How I treat thrombocytopenic purpura (ITP). Blood 2005;106:2244-51.
8. Kojouri K, Vesely SK, Terrell D, George J. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to asses long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623-34.
9. Vesely SK, Erdue JJ, Rizvi MA, Terrell D, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy. Ann Int Med 2004;140:112-20.
10. Arnold D, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33.
11. Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of therapeutic strategy for adult with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Hematologica 2005;90:810-4.
12. Duperier T, Brody F, Felsher J, Walsh RM, Rosen M, Ponsky J. Predictive factors for successful laparoscopic splenectomy in patients with immune thrombocytopenic purpura. Arch Surg 2004;139:61-6.
13. Stasi R, Stipa E, Masi M, Cecconi M, Scimo MT, Oliva F, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436-2.
14. Portielje J, Westendorp R, Klui-Nelemans H, Brand A. Morbility and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549-54.
15. Michel M, Khellaf M, Desorges L, Lee K, Schaeffer A, Goudeau B, et al. Autoimmune thrombocytopenic purpura and Helicobacter pylori infection. Arch Inter Med 2002;162:1033-6.
16. Wani NA, Parray FQ. Therapeutic splenectomy in immune thrombocytopenic purpura. W J Surg 2000;24:92-4.
17. Vianelli N, Valdrè L, Fiacchini M, De Vivo A, Gugliotta L, Catani L, et al. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologica 2001;86:504-9.
18. Zimmer J, Andres E, Noel E, Koumarianou A, Blicklè JF, Maloisel F. Current management of adult idiopathic trombocytopenic purpura in practice: a cohort study of 201 patients from a single center. Clin Lab Haem 2004;26:137-42.
19. Veneri D, Franchini M, Gottadi M, D'Adda M, Ambrosetti A, Krampera M, et al. Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica 2002;87:1177-9.
20. Andres E, Zimmer J, Noel E, Kaltenbach G, Koumarianou A, Malosel F. Idiopathic thrombocytopenic purpura. A retrospective analysis in 139 patients of the influence of age on response to corticosteroids, splenectomy and danazol. Drug Aging 2003;20:841-6.
21. Balanguè C, Vela S, Targarono EM, Gich IJ, Muniz E, D'Ambra A, et al. Predictive factors for successful splenectomy in immune thrombocytopenic purpura. Surg Endosc 2006; 20:1208-13.
22. Bourgeois E, Caulier M, Delarozese C, Brouillard M, Bauters F, Fenaux P. Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis. Br J Haematol 2003;120:1079-88.
23. Stasi R, Provan D. Managment of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004; 79: 504-22.
24. Pizzutto J, Ambriz R. Therapeutic Experiece on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the Cooperativa Latin American Group on Hemostasis and Thrombosis. Blood 1984; 64:1179-83.
25. Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults- a report on 90 patients. Eur J Haematol 2005; 75:328-31.
26. George J. Idiopathic thrombocytopenic purpura in adult: current issues for pathogenesis, diagnosis and management. Hematol J 2004;5-S12-S14.
27. George JN, Raskob GE, Vesely SK, Moore D, Lyons RM, Cabos E, et al. Initial management of immune thrombocytopenic purpura in adults: a randomised controlled trial comparing intermittent anti-D with routine care. Am J Hematol 2003;74:161-9.
28. Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Br J Haematol 2002; 118:933-44.
29. Emilia G, Morselli M, Luppi M, Longo G, Marasca R, Gandini L, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood 2002;99:1482-5.
30. Scaradavou A, Woo B, Woloski BMR, Cunningham-Rundles S, Ettinger LJ, Aledort AM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patiens. Blood 1997; 89:2689-700.
31. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997;126:307-14.
32. George JN, El-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994; 331:1207-11.
33. McMillan. Classical management of refractory adult immune (idiopathic) thrombocytopenic purpura. Blood Rev 2002;16:51-5.
34. Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of post-splenectomy relapses. Ann Hematol 2002;81:312-9.
35. Godeau B, Chevret S, Varet B, Lefrere F, Zini JM, Bassompierre F, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomized multicentre trial. Lancet 2002;359:23-9.
36. Bellucci S, Charpak Y, Chanstang C, Tobelem G. low doses versus conventional doses of corticoids in immune thrombocytopenic purura (ITP): results of a randomised clinical trial in 160 children, 223 adults. Blood 1988;71:1165-69.
37. Radaelli F, Calori R, Goldaniga M, Guggiari E, Luciano A. Adult refractory chronic idiopathic trhombocytopenic purpura: can Dapsone be proposed as secondary-line therapyinverted ? sign Br J Haematol 1999; 104:641-5.
38. Michel M, Cooper N, Jean C, Frissora C, Bussel JB. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpurainverted ? sign Blood 2004; 103:890-6.
39. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 2006; 81:19-25.
40. Sailer T, Weltermann A, Zoghlami C, Kyrle PA, Lechner K, Pabinger I. Mortality in severe, non aggressively treated adult autoimmune thrombocytopenia. Hematol J 2003; 4:366-9.
41. Cooper N, Michael B, Woloski R, Fodero E, Novoa M, Leber M, et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adult with recendy diagnosed immune thrombocytopenic purpura to avoid splenectomyinverted ? sign Blood 2002;99:1922-7.
42. Godeau B, Caulier MT, Decuypere L, Rose C, Schaeffer A, Bierling P. Intravenous immunoglobulin for autoimmune thrombocytopenic purpura: results of a randomised trial comparing 0.5 and 1 g/Kg b.w. Br J Haematol 1999;107:716-9.
43. Rosse WF. Clinical management of adult ITP prior to splenectomy: a perspective. Blood Rev 2002;16:47-9.
44. Cheng Y, Wong R, Yoo J, Chui C, Lau F, Chan N, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003;349:831-6.
45. Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991;77:31-3.
46. George JN. Initial management of adults with idiopathic (immune) thrombocytopenic purpura. Blood Rev 2002;16:37-8.
47. Neylon A, Saunders PWG, Howard MR, Proctor SL, Taylor PRA. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122:966-74.
48. Emilia G, Morselli M, Luppi M, Longo G, Marasca R, Gandini G, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood 2002;99:1482-5.
49. Alpdagan O, Alpdogan TB, Ratip S, et al. Efficacy of high-dose methylprednisone as a first-line therapy in adult patiens with idiopathic thrombocytopenic purpura. Br J Hematol 1998; 103:1061-3.
50. Jacobs P, Wood L, Novitzky N. Intravenous gammaglobulin has advantages over corticosteroids as primary therapy for immune thrombocytopenia: a prospective randomised clinical trail. Am J Med 1994;97:55-9.
51. Law C, Marcaccio M, Tam P, Heddle N, Kelton J. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med 1997;336:1494-8.
52. Louwes H, Vellenga E, Houwerzijl EJ, de Wolf JT. Effects of prednisone and splenectomy in patients with idiopathic thrombocytopenic purpura: only splenectomy induces a complete remission. Ann Hematol 2001;80: 728-32.
53. Choi CW, Kim BS, Seo JH et al. Response to high-dose intravenous immune globulin as a valuable factor predicting the affect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. Am J Hematol 2001;66:197-202.
54. Johansson E, Engervall P, Landgren O, Grimfors G, Widell S, Rezai S, et al. Response to splenectomy is durable after a certain point in time in adult patients with chronic immune thrombocytopenic purpura. Eur J Haematol 2006;77:61-6.
55. Kojouri K, Vesely SK, Terrel DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623-34.
56. Wang T, Xu M, Ji L, Han ZC, Yang R. Splenectomy for adult chronic idiopathic thrombocytopenic purpura: experience from a single center in China. Eur J Haematol 2005;75:424-9.
57. Bussel JB. Novel approaches to refractory immune thrombocytopenic purpura. Blood Rev 2002;16:31-6.
58. George JN, Kojouri K, Perdue JJ, Vesely SK. Management of patients with chronic, refractory thrombocytopenic purpura. Semin Hematol 2000;37:290-8.
59. Hou M, Peng J, Shi Y, Zhang C, Qun P, Zhao C, et al. Mycophenolate mofetil (MMF) for treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 2003;70:353-7.
60. Sato R, Murakami K, Watanabe K, Okimoto T, Miyajima H, Ogata M, et al. Effect of Helicobacter pylori eradication on platelet recovery in patiens with chronic idiopathic thrombocytopenic purpura. Arch Intern Med 2004;164:1904-7.
61. Szold A, Kais H, Keidar A, Nadav L, Eldor A, Klausner JM. Chronic idiopathic thrombocytopenic purpura (ITP) is a surgical disease. Surg Endosc 2002;16:155-8.
62. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001;114:121-5.
63. Godeau B, Durand JM, Roudot-Thoraval F, Tenneze A, Oksenhendler E, Kaplanski G, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. B J Haematol 1997;97:336-9.
64. Snyder HW, Cochran SK, Balint JP, Bertram JH, Mittelman A, Guthrie TH, Jones F. Experience with protein A-Immunoadsorption in treatment-resistance adult immune thrombocytopenic purpura. Blood 1992;79:2237-45.
65. Bussel JB, Pham LC, Aledort L, Nachman R. Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusion of gammaglobulin. Blood 1988; 72: 121-7.
66. Huhn R, Fogarty P, Nakamura R, Read E, Leitman E, Rick M, et al. High-dose cyclophoshamide with autologous lymphocyte-depleted peripheal blood stem cell (PBSC) support for refractory chronic autoimmune thrombocytopenia. Blood 2003;101:71-7.
67. Bell WR, Role of splenectomy in immune (idiopathic) thrombocytopenic purpura. Blood Rev 2002;16:39-41.
68. Bresler L, Guerci A, Brunaud L, Ayav A, Sebbag H, Tortuyaux JM, et al. Laparoscopic splenectomy for idiopathic thrombocytopenic purpura: outcome and long-term results. World J Surg 2002;26:111-4.
69. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004;104:956-60.
70. Schwartz J, Leber M, Gillis S, Giunta A, Eldor A, Bussel JB. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003; 72:94-8.
71. Gibson M, Sehon JK, White S, Zibari GB, Johnson LW. Splenectomy for idiopathic thrombocytopenic purpura: a five-year retrospective review. Am Sure 2000;66:952-4.
72. Zoghlami-Rintelen C, Weltrmann A, Bittermann C, Kyrle PA, Pabinger I, Lechner K, et al. Efficacy and safety of splenectomy in adult chronic immune thrombocytopenia. Ann Hematol 2003;82:290-4.
73. Braendstrup P, Bjerrum OW, Nielsen OJ et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopahic thrombocytopenic purpura. Am J Hematol 2005;78:275-80.
74. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004; 125:232-9.
75. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952-7.
76. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994;331: 1560-4.
77. Giagounidis AAN, Schneider P, Germing U, Sohgen D, Quabeck K, Aul C. Treatment of relapse idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002;69:95-100.
78. Cahill MR, Macey MG, Cavenagh JD, Newland AC. Protein A immunoadsorption in chronic refractory ITP reverses increased platelet activation but fail archive sustained clinical benefit. Br J Haematol 1998;100:358-64.
79. McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med 2001;344:1402-3.
80. Berchtold P, McMillan R. Therapy of chronic idiopatic thrombocytopenic purpura in adults. Blood 1989; 74:2309-17.
81. Suzuky T, Matsushima M, Masui A, Watanabe K, Takagi A, Ogawa Y, et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomised controlled trial. Am J Gastroenterol 2005;100:1271-3.
82. Shanafelt T, Madueme H, Wolf R, Tefferi A. Rituximab for immune thrombocytopenic purpura, autoimmune haemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003; 78:1340-6.
83. Figueroa M, Gehlsen J, Ondreyco S, Piro L, Pomeroy T, Williams F, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 1993; 328:1226-9.
84. Stasi R, Amadori S, Osborn J, Newland AC, Provan D. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med 2006;3:e24.